国产之光,科伦博泰HER2 ADC突围二线及以上全人群HER2阳性乳腺癌

药械Talks
Dec 12, 2025

10月17日,科伦博泰宣布其自主研发的HER2靶向ADC药物——博度曲妥珠单抗(A166,舒泰莱®)正式获批上市,成为继TROP2 ADC之后,该公司获批的第二款ADC产品。此次获批不仅是科伦博泰在ADC领域持续深耕、不断突破的有力见证,更是国产ADC在HER2阳性晚期乳腺癌治疗这一关键战场上实现“全面突围”的重要里程碑。根据获批适应症,博度曲妥珠单抗将用于既往接受过一种或一种以上抗HER2药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10